Can an immunotherapy combo turn inoperable gallbladder cancer into a surgical success?

This phase II trial is testing whether adding an experimental immunotherapy drug called AK112 to a standard chemotherapy regimen (gemcitabine, cisplatin, and albumin-bound paclitaxel) can shrink locally advanced gallbladder tumors enough to allow surgery. Adults with gallbladder cancer that is initially too advanced for curative surgery will receive the combination every three weeks for 4-6 cycles. The main goal is to see how often the treatment enables a complete surgical removal (R0 resection), while also monitoring tumor response and safety.